Jean Jacques Bienaime - Dec 21, 2023 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Director
Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Dec 21, 2023
Transactions value $
-$308,900
Form type
4
Date filed
12/22/2023, 05:14 PM
Previous filing
Nov 9, 2023
Next filing
Feb 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $631K +10K +2.35% $63.10 435K Dec 21, 2023 Direct F1
transaction BMRN Common Stock Sale -$940K -10K -2.3% $93.99 425K Dec 21, 2023 Direct F1
holding BMRN Common Stock 247K Dec 21, 2023 Shares held by Jean-Jacques Bienaime Family Trust
holding BMRN Common Stock 100 Dec 21, 2023 Shares held as UTMA custodian for child 1
holding BMRN Common Stock 100 Dec 21, 2023 Shares held as UTMA custodian for child 2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -10K -5.24% $0.00 181K Dec 21, 2023 Common Stock 10K $63.10 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on August 7, 2023.
F2 Reflects the number of options outstanding after the transactions from this specific stock option grant.